Knight Therapeutics Inc. (TSE:GUD – Get Free Report) Senior Officer Amal Khouri sold 10,000 shares of Knight Therapeutics stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of C$5.72, for a total transaction of C$57,200.00.
Amal Khouri also recently made the following trade(s):
- On Monday, June 10th, Amal Khouri sold 20,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00.
Knight Therapeutics Price Performance
TSE GUD traded down C$0.01 during trading hours on Wednesday, hitting C$5.71. 20,948 shares of the company’s stock traded hands, compared to its average volume of 68,072. The company has a debt-to-equity ratio of 9.20, a current ratio of 3.34 and a quick ratio of 1.79. The firm’s 50-day moving average is C$5.81 and its 200-day moving average is C$5.59. Knight Therapeutics Inc. has a 52-week low of C$4.35 and a 52-week high of C$6.22. The company has a market capitalization of C$578.88 million, a PE ratio of -35.75, a PEG ratio of -1,013.50 and a beta of 0.46.
Wall Street Analyst Weigh In
A number of analysts have recently commented on GUD shares. Raymond James boosted their target price on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a research note on Wednesday, March 6th. Stifel Nicolaus lifted their price target on Knight Therapeutics from C$5.40 to C$5.75 in a research note on Friday, May 10th. Finally, Royal Bank of Canada increased their price objective on Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd.
Read Our Latest Analysis on Knight Therapeutics
About Knight Therapeutics
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
See Also
- Five stocks we like better than Knight Therapeutics
- Investing in the High PE Growth Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Retail Stocks Investing, Explained
- GitLab Stock Rebounds: The Inside Story of Its Comeback
- Insider Trades May Not Tell You What You Think
- Is Rivian Stock on the Verge of a 100% Rally?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.